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Background: Polymorphisms in cytochrome P450 2B6 (CYP2B6) affect the steady state plasma concentration of
nevirapine. CYP2B6 516G>T and 983T>C are common in African populations, but data on their influence on plasma
nevirapine concentration and clinical response in African women are limited. We investigated the impact of CYP
516G>T and 983T>C on plasma nevirapine concentration and clinical outcomes in a prospective cohort study of
HIV-infected Kenyan women.
Methods: Study subjects were 66 HIV-1-seropositive women taking nevirapine-based antiretroviral therapy. Plasma
collected at week 12 was analyzed for nevirapine concentration by high performance liquid chromatography.
Baseline samples were genotyped for CYP2B6 516G>T and 983T>C single nucleotide polymorphisms by real-time
polymerase chain reaction. CD4 cell count, plasma viral load, and genotypic drug resistance in plasma and genital
secretions were assessed at baseline and during follow up. We evaluated the effect of each genotype on plasma
nevirapine concentration at week 12 and on change in CD4 cell count at months 3, 6 and 12. Associations between
plasma nevirapine concentration and clinical outcomes were analyzed by logistic or linear regression.
Results: Women with CYP2B6 516TT genotype (n=9) had higher mean nevirapine plasma levels (14.33 μg/mL)
compared to those with heterozygous 516GT (9.18 μg/mL; n=25) and wild- type 516GG (7.95 μg/mL; n=32) genotypes
(P=0.01). Women heterozygous for the CYP2B6 983TC genotype (n=13) had higher mean nevirapine plasma levels
(12.94 μg/mL), compared to women with the homozygous 983TT (8.35 μg/mL; n=53) genotype (P=0.007). In Generalized
Estimating Equation analysis, plasma nevirapine levels predicted greater change in CD4 cell count after ART initiation
(adjusted beta 119.4 cells/μL, 95% CI, 27.3–211.5 cells/μL, P=0.01). The CYP2B6 983TT genotype also predicted greater
change in CD4 cell count (adjusted beta 68.6 cells/μL, 95% CI, 3.9–133.4 cells/μL, P=0.04). We found no associations
between CYP2B6 genotypes and virologic response or toxicity.
Conclusions: CYP2B6 516G>T and CYP2B6 983T>C genotypes were strongly associated with plasma nevirapine
concentration, which predicted immunologic response in women on nevirapine-based antiretroviral therapy. These
data support continued work on the potential utility of human genetic testing to inform nevirapine dosage
optimization for individual patients.
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Table 1 Baseline characteristics of study participants at
initiation of nevirapine-based antiretroviral therapy
Characteristic Median (IQR) or N (%)
Age (yrs) 36 (32–40)
Weight (kg) 65 (54 – 70)
BMI (kg/m2) 25.0 (22.3 – 28.2)
CD4 cell count (cells/μL) 126 (79 – 154)
Plasma viral load (log10 copies/mL) 5.54 (5.17 – 5.90)
Cervical viral load (log10 copies/mL) 4.04 (3.42 – 4.60)
ALT levels (>ULN) 11 (15.9)
Skin rash 11 (15.9)
Plasma resistance (present) 0
Genital resistance (present) 0
ART regimen: d4T/3TC/NVP 69 (100)
BMI = body mass index, ALT = alanine aminotransferase, ULN = upper limit of
normal, ART = antiretroviral therapy, NVP = nevirapine, d4T = stavudine,
3TC = lamivudine.
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Sub-Saharan Africa remains severely affected by HIV, ac-
counting for 69% of people living with HIV worldwide
[1]. The HIV epidemic in Kenya disproportionately af-
fects women, with prevalence (8.0%) nearly twice that
of men (4.3%) [2]. This difference is reflected in the
large number of women accessing HIV care and treat-
ment with antiretroviral drugs [3]. Over 70% of patients
on first-line antiretroviral therapy (ART) in Kenya take
a nevirapine-based regimen [3,4]. This is due to its rela-
tively low cost, manageable pill burden and excellent ef-
ficacy [5]. However, the use of nevirapine is limited by a
potentially fatal immune-mediated hypersensitivity reac-
tion that manifests as hepatotoxicity, fever, and/or skin
rash,[6] and by a fragile genetic barrier to the develop-
ment of drug resistance [7]. Furthermore, not all patients
treated with nevirapine experience optimal response.
The etiology of sub-optimal response is multi-factorial
and may include differences in adherence, gender, con-
comitant medications and genes responsible for drug
metabolism [8,9].
Nevirapine undergoes oxidative metabolism primarily
by cytochrome P450 3A4 (CYP3A4) and 2B6 (CYP2B6),
with a minor contribution by 3A5 (CYP3A5) [10,11].
CYP2B6 metabolic activity is subject to the influence of
several genetic polymorphisms, as well as strong inhibi-
tors and inducers, contributing to highly variable plasma
drug exposure [12-14]. CYP2B6 genetic polymorphisms
may be more important in African populations. For ex-
ample, the single nucleotide polymorphism (SNP)
CYP2B6 516G>T (rs3745274), which reduces hepatic
CYP2B6 protein expression and activity [15], occurs
more frequently in African populations than in Cauca-
sian and Asian populations [16-18]. Moreover, CYP2B6
983T>C (rs28399499), which is a null allele [12], is ab-
sent in Caucasians but has a prevalence of 4%–11% in
African populations [18,19].
Nevirapine exhibits large inter-individual variability in
its pharmacokinetics [20], contributing to variable out-
comes among HIV-infected patients. Sub-therapeutic
plasma concentrations are associated with treatment fail-
ure and the emergence of antiretroviral drug resistance,
whereas supra-therapeutic concentrations are associated
with toxicity [21]. Several studies have evaluated associa-
tions between CYP2B6 516G>T and CYP2B6 983T>C
SNPs and steady-state plasma nevirapine levels [22-24].
However, prospective studies evaluating the influence of
CYP2B6 polymorphisms on clinical response among
HIV-infected African women taking nevirapine-based
ART are lacking.
In the present study, we investigated the impact of
CYP2B6 516G>T and CYP2B6 983T>C genetic variants
on plasma nevirapine levels and clinical outcomes in-
cluding change in CD4 cell count, plasma viral load(PVL), and the incidence of antiretroviral resistance mu-
tations and adverse reactions.
Results
Baseline characteristics and plasma nevirapine levels
Sixty-nine of the 73 women screened met the inclusion
criteria and were tested for CYP2B6 genotypes. Four
women who had not been prescribed a nevirapine-based
regimen for at least 12 weeks were excluded from ana-
lysis. Baseline characteristics of study participants at
ART initiation are shown in Table 1. The median age at
ART initiation was 36 (inter-quartile range [IQR] 32–40)
and the median CD4 count was 126 cells/μL (IQR 79–
154 cells/μL). Abnormal alanine aminotransferase (ALT)
levels and skin rash were each present in 11 (16%) of
the women at baseline. No baseline plasma or genital
drug resistance was detected.
Sixty-six of the 69 women in this study had detectable
nevirapine levels at week 12. Three women who had un-
detectable levels were assumed to be non-adherent and
were excluded from further analysis. Steady-state plasma
nevirapine levels were characterized by wide inter-
individual variability, ranging from 1.68 μg/mL to
23.12 μg/mL (median 9.14 μg/mL, IQR 5.98–2.46 μg/
mL). No significant correlation was found between
log10-transformed plasma nevirapine levels and age
(P=0.78) or body mass index (BMI, P=0.19).
Frequency of CYP2B6 genotypes
For the CYP2B6 516G>T SNP, the frequency of the T
variant allele was 31.2% (95% CI, 23.6%–39.6%). The
number of subjects with GG, GT and TT genotypes were
35 (50.7%), 25 (36.2%), and 9 (13.0%), respectively. For
the CYP2B6 983T>C SNP, the frequency of the C vari-
ant allele was 10.1% (95% CI, 5.7%–16.4%). Most
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type TT genotype, whereas 14 women (20.3%) had the
heterozygous mutant TC genotype and none had the
homozygous mutant CC genotype. CYP2B6 516G>T
polymorphism met Hardy-Weinberg (HW) equilibrium
expectations (P=0.26). HW equilibrium could not be
tested for CYP2B6 983T>C, because the homozygous mu-
tant was not detected in this population. There was no
evidence of linkage disequilibrium between rs3745274
and rs28399499 (Fisher’s exact P=0.45). In terms of in-
ferred phenotypes, 26 (37.7%) individuals were pre-
dicted to be extensive metabolizers, 31 (44.9%) to be
intermediate metabolizers, and 12 (17.4%) to be slow
metabolizers.
CYP2B6 516G>T and 983T>C genotypes and plasma
nevirapine levels
Among the 66 women with detectable plasma nevirapine
levels, CYP2B6 516G>T and 983T>C SNPs were associ-
ated with higher mean plasma nevirapine levels at week
12 (Table 2). A gene-dose effect was evident in the
distribution of plasma nevirapine levels among CYP2B6
516G>T and CYP2B6 983T>C genotypes. Mean plasma
nevirapine levels were higher among individuals who
were homozygous for the mutation (CYP2B6 516TT,Table 2 CYP2B6 516G>T and 983T>C genotypes and
plasma nevirapine concentrations






GG 32 (48.5) 7.95 (6.59-9.60)
GT 25 (37.9) 9.18 (7.52-11.20)
TT 9 (13.0) 14.33 (9.94-20.67)
TOTAL 66 0.01*
CYP2B6 983T>C
TT 53 (80.3) 8.35 (7.33-9.64)




Extensive metabolizers 24 (36.4) 6.92 (5.70-8.41)
Intermediate metabolizers 30 (45.5) 9.34 (7.78-11.20) 0.02†
Slow metabolizers 12 (18.2) 14.76 (11.38-19.19) <0.0001†
TOTAL 66
*Comparison across groups using Stata’s qtlsnp command.
†ANOVA comparing either intermediate or slow metabolizers to extensive
metabolizers (reference category).14.33 μg/mL) and in those who were heterozygous for
the mutation (CYP2B6 516GT, 9.18 μg/mL) compared
to those with the wild-type (CYP2B6 516GG, 7.95 μg/
mL, P=0.01 across groups). A similar trend was ob-
served for CYP2B6 983T>C, with mean plasma nevi-
rapine levels being higher among individuals
expressing the heterozygous genotype (CYP2B6
983TC, 12.94 μg/mL) compared to those with the
homozygous wild-type (983TT, 8.35 μg/mL, P=0.01
across groups). With regard to the phenotypes, mean
plasma nevirapine levels were higher among individ-
uals classified as slow metabolizers (14.76 μg/mL, P <
0.01 compared to extensive metabolizers) and among
individuals classified as intermediate metabolizers
(9.34 μg/mL, P=0.02 compared to extensive metaboli-
zers). The relationships between log10-transformed
plasma nevirapine concentrations and CYP2B6 geno-
types or phenotypes are summarized in Figures 1a, b
and c.
Plasma nevirapine levels predicted greater change in CD4
cell count
Higher plasma nevirapine levels were significantly corre-
lated with greater change in CD4 cell count from base-
line to month 3 (P=0.02) and month 6 (P=0.02), but
not month 12 (P=0.07). In Generalized Estimating
Equation (GEE) analysis with adjustment for baseline
CD4 cell count, month since ART initiation, and time-
updated adherence by pill count, plasma nevirapine
levels predicted greater change in CD4 cell count after
ART initiation (adjusted beta 119.4 cells/μL, 95% CI,
27.3 to 211.5 cells/μL, P=0.01).
CYP2B6 983T>C genotype was associated with greater
change in CD4 cell count
There was no difference in CD4 cell count at baseline
between the two CYP2B6 983T>C genotype groups
(mean 120 for TC, mean 123 for TT, p=0.88). Using
Stata’s qtlsnp command, CYP2B6 983T>C genotypes
were associated with mean change in CD4 cell count
at month 3 (P=0.01), month 6 (P=0.02) and month
12 (P=0.02). In GEE analysis with adjustment for
baseline CD4 cell count, month since ART initiation,
and time-updated adherence by pill count, the TT
genotype predicted greater change in CD4 cell count
(adjusted beta 68.6 cells/μL, 95% CI, 3.9 to 133.4
cells/μL, P=0.04) during follow-up (Table 3). Adjust-
ment for log10-transformed plasma nevirapine level di-
minished this effect, as shown in the last column of
Table 3.
There were no differences between baseline CD4 cell
count for the three CYP2B6 516G>T genotype groups
(mean 127 for GG, 108 for GT, and 142 for TT, p=
0.26). Interestingly, CYP2B6 516G>T genotypes had
Figure 1 Differences in log10-transformed plasma nevirapine
levels by genotype. Panel A, Log10-transformed plasma nevirapine
levels for each CYP2B6 516G>T genotype: GG, GT, and TT. Panel B,
Log10-transformed plasma nevirapine levels for each CYP2B6 983T>C
genotype: TC and TT. Panel C, Log10-transformed plasma nevirapine
levels for each CYP2B6 phenotype (predicted from CYP2B6 516G>T
and 983T>C genotypes). EM= extensive metabolizer, IM = intermediate
metabolizer, SM= slow metabolizer.
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count at month 3 (P=0.86), month 6 (P=0.61), or
month 12 (P=0.54) in this population. This lack of ef-
fect was confirmed in a GEE model (results not
shown).No correlation between plasma nevirapine levels and
virologic response
There were no correlations between plasma nevirapine
levels and change in PVL at month 3 (P=0.95), month
6 (P=0.53), or month 12 (P=0.81). In GEE analysis
with adjustment for baseline PVL, month since ART
initiation, and time-updated adherence by pill count,
no association between plasma nevirapine levels and
change in PVL was found (data not shown). T test
comparisons showed no associations between plasma
nevirapine levels and viral suppresion at month 3 (P=
0.38), month 6 (P=0.59), or month 12 (P=0.45). In
GEE analysis with adjustment for baseline PVL,
month since ART initiation, and time-updated adher-
ence by pill count, there was no association between
plasma nevirapine levels and viral suppression (data
not shown).
Genotypic resistance was not detected in plasma or
genital secretions of study participants at baseline. Dur-
ing follow-up, four (5.8%) and three (4.4%) women de-
veloped genotypic resistance in plasma and in genital
secretions, respectively. Plasma nevirapine levels were
not associated with resistance in either plasma (odds ra-
tio [OR] 0.55, 95% CI 0.004–81.94, P=0.81) or genital
tract secretions (OR 3.94, 95% CI 0.006–2497.02, P=
0.68). Adjustment for baseline CD4 cell count and ad-
herence or for baseline PVL and adherence did not
change these findings.Plasma nevirapine levels did not predict hepatotoxicity or
skin rash
Of the 69 study participants, 11 (15.9%) had abnormal
ALT levels at baseline which persisted through follow-
up. Of the 58 women who had normal ALT levels at
baseline, 14 (24.1%) had abnormal ALT levels that de-
veloped during follow-up. Plasma nevirapine levels were
not significantly associated with the development of
hepatotoxicity during follow-up, despite an increased
odds (OR 5.35, 95% CI 0.27–106.01, P=0.27). Adjust-
ment for adherence, hepatitis B, and baseline CD4 count
did not change this result (adjusted odds ratio [aOR]
2.88, 95% CI 0.13–62.95, P=0.50). No correlation was
found between plasma nevirapine levels and maximum
ALT levels recorded during ART (ρ=0.129, P=0.30,
Figure 2). Eleven (15.9%) of the 69 study participants
had a skin rash at baseline that persisted over the
follow-up period. Of the 58 women with no skin rash at
baseline, 27 (46.6%) developed skin rash during follow-
up. Plasma nevirapine levels were not associated with a
new skin rash (OR 0.36, 95% CI 0.03–3.88, P=0.40).
Adjustment for adherence and baseline CD4 count did
not change these results (aOR 0.44, 95% CI 0.03–5.97,
P=0.54).
Table 3 CYP2B6 983T>C genotype and change in CD4 cell count over the 12-month follow-up period
Variable Unadjusted beta P value Adjusted beta* P value Adjusted beta† P value
CYP2B6 983T>C
TT genotype reference reference reference
TC genotype 68.2 (3.3 to 133.0) 0.039 68.6 (3.9 to 133.4) 0.038 57.6 (−4.6 to 119.8) 0.069
Baseline CD4 count 0.0 (−0.4 to 0.5) 0.920 0.0 (−0.4 to 0.4) 0.831 0.1 (−0.3 to 0.5) 0.595
Months since ART initiation 3.3 (0.8 to 5.8) 0.010 3.4 (1.0 to 5.8) 0.005 3.6 (1.1 to 6.0) 0.004
Pill count adherence 0.3 (−1.6 to 2.1) 0.768 0.8 (−1.0 to 2.5) 0.384 0.7 (−1.4 to 2.8) 0.521
Log10-tranformed nevirapine levels 115.3 (26.6 to 204.1) 0.011 85.9 (10.6 to 161.3) 0.025
*Adjusted for all factors included in model.
†With added adjustment for log10 plasma nevirapine levels.
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This prospective study analyzed the association between
CYP2B6 516G>T and CYP2B6 983T>C genotypes,
plasma nevirapine levels, and clinical response in a well-
characterized cohort of HIV-1-positive Kenyan women
on first-line nevirapine-based ART. The prevalence of
CYP2B6 516T and CYP2B6 983C variants in this popu-
lation was similar to that reported for other African pop-
ulations and Kenyan ethnic groups [17,18]. We observed
a significant association between both CYP2B6 516G>T
and CYP2B6 983T>T genotypes and higher plasma nevi-
rapine concentrations. In addition, plasma nevirapine
levels significantly predicted change in CD4 cell counts
after ART initiation. Furthermore, CYP2B6 983TC het-
erozygosity was associated with greater increase in CD4
cell count over the 12-month follow-up period.
CYP2B6 983T>C occurs predominantly in African
subjects, with allele frequencies of 4% to 11% [19,20].
Homozygosity for the mutant allele CYP2B6 983 CC
was not detected in this population, in concurrence withFigure 2 Scatterplot of log10-transformed plasma nevirapine levels ana previous study [25]. However, heterozygosity for the
mutation CYP2B6 983TC was associated with higher
plasma nevirapine levels in our study, with heterozygous
TC individuals having levels 55% higher than those with
the wild type TT. This effect is noteworthy for its mag-
nitude, especially when compared to the smaller effect
observed for CYP2B6 516GT (16%). The CYP2B6
983T>C (rs28399499) SNP results in the variant protein
CYP2B6*18 with an I328T as the only amino acid
change. Its expression in vitro results in no detectable
protein or activity [26], and it has been designated as a
null allele [12]. This null status could explain the greater
impact of CYP2B6 983TC compared to the CYP2B6
516GT. In agreement with our results, other studies
have reported that CYP2B6 983TC heterozygosity leads
to reduction in nevirapine clearance [27,28].
We also made an observation that heterozygosity for
CYP2B6 983TC was significantly associated with greater
increase in CD4 cell count during follow-up. This obser-
vation could be attributed to the fact that CYP2B6d log10-transformed maximum ALT levels during ART.
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levels, which in turn were associated with greater in-
crease in CD4 cell count, particularly in the early
months of ART. In fact, from our multivariable analysis,
the addition of plasma nevirapine levels to the model
weakened the association between genotype and change
in CD4 cell count, providing evidence of at least partial
mediation of this association by nevirapine levels.
Previous studies evaluating the impact of CYP2B6 ge-
notypes on clinical outcomes have reported varied re-
sults. A study by Haas et al. [29] reported no association
between CYP2B6 516G>T genotypes and change in CD4
cell count, in concurrence with our findings. However,
in a HIV-1-positive pediatric cohort, CYP2B6 516TT
genotype was associated with greater increase in CD4
cell count percentage at week 12, compared to those
with the GT and GG genotypes (9.0% vs. 5.0% vs. 3.2%
increases, respectively) [30]. More recent studies report
a significant association between the CYP2B6 516 T al-
lele, UGT2B7*2, higher efavirenz plasma levels and
change in CD4 cell count in HIV-1 positive African pa-
tients in Tanzania and Ethiopia [31]. These studies did
not include testing for CYP2B6 983T>C. Hence, our
study is the first to report a significant association be-
tween CYP2B6 983TC heterozygosity and greater in-
crease in CD4 cell count in an African population.
It is unclear why nevirapine concentrations would influ-
ence CD4 cell recovery but not have a detectable effect on
viral load reduction or suppression. At least one study of
patients with virologic suppression on nevirapine has
highlighted nevirapine’s ability to penetrate reservoir sites
and achieve high intracellular concentrations, leading to
extremely low levels of viral replication [32]. It is possible
that penetration into reservoir sites varied by genotype in
this study, leading to an impact on CD4 T cell recovery
that was independent of the effect on plasma viral load.
Alternatively, because most women achieved virologic
suppression and there were no differences in baseline
plasma viral load prior to ART initiation, there may have
been a floor effect on change in plasma viral load that re-
duced our power to detect differences by genotype. In
contrast, our study participants initiated therapy with very
low CD4 counts which increased during ART and reached
no ceiling during the 12 months of follow-up. We may,
therefore, have had more power to detect differences in
CD4 cell recovery. A third explanation is that some other
genetic trait linked to the CYP2B6 983T>C phenotype
somehow influences CD4 T cell recovery. This is a poten-
tial area of investigation, should our results be confirmed
in other studies.
A major strength of our study was its design as a pro-
spective study in a well-characterized cohort in which
clinical outcomes were carefully measured and recorded.
Our study also had a number of limitations. First, sub-optimal adherence could have contributed to the ob-
served wide inter-patient variability in plasma nevirapine
levels. Second, plasma nevirapine levels could also be
under the influence of other drug metabolism and mem-
brane transporter genes which were not studied in our
cohort. Third, we do not have information on nutritional
status, herbal remedies, or medications obtained outside
the research clinic that may have influenced immune re-
sponse. Fourth, our sample size and duration of follow-
up were limited, and we may have failed to detect
smaller differences in some outcomes. Despite these lim-
itations, we were able to identify several clinical corre-
lates that were associated with participant genotypes.
Conclusions
In conclusion, we have found in this study that CYP2B6
516G>T and 983T>C genotypes are associated with
higher plasma nevirapine exposure in HIV-1 infected
Kenyan women, and that higher plasma nevirapine levels
and the CYP2B6 983TC genotype were associated with
better immunologic response. In this study, neither
plasma nevirapine levels nor CYP2B6 genotypes were
significantly associated with toxicity or with the emer-
gence of plasma or genital resistance. However, our
follow-up time was limited and the incidence of both tox-
icity and drug resistance was fairly low. We recommend
further studies to confirm the role of CYP2B6 genotypes
and other relevant genes in the pharmacokinetics and
clinical response to nevirapine in HIV-1-positive African
women.
Methods
Study population and design
The study was nested within an ongoing prospective co-
hort study investigating the impact of ART on HIV-1 in-
fectivity in female sex workers in Mombasa, Kenya
[33,34]. At the time of this study, ART was initiated for
women with CD4 counts ≤200 cells/μL or an AIDS de-
fining illness [35]. Pregnant women were excluded and
instead referred to programs offering ART for the preven-
tion of mother to child transmission. Women requiring
rifampicin-containing treatment for active tuberculosis
were prescribed efavirenz or a triple non-nucleoside
reverse transcriptase inhibitor regimen, according to WHO
guidance at the time [35]. All women were prescribed
co-trimoxazole prophylaxis, unless contraindicated.
The standard ART regimen included nevirapine
200 mg daily for 14 days, then 200 mg twice daily [35].
The NRTI backbone included stavudine or zidovudine
plus lamivudine at standard doses [35]. Adherence was
promoted by directly observed administration of one of
the two daily doses to the women on weekdays during
their first month of ART. Pill box organizers and a monthly
support group were also used to enhance adherence, which
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visual analogue scale [36]. Fluconazole, which can impact
nevirapine levels, was prescribed for only one woman in
this study, starting at the month 6 visit.
Clinical response to treatment was monitored, includ-
ing self-reported symptoms and physical examination
(including rash). Laboratory testing, including regular
testing of CD4 cell count, hemoglobin, ALT, creatinine,
and plasma and genital viral load, were performed on
stored samples from baseline, month 3, month 6, and
month 12 [33,34]. Samples with detectable HIV-1 ribo-
nucleic acid (RNA) after treatment initiation were evalu-
ated for antiretroviral resistance mutations.
All HIV-1-seropositive women who initiated nevirapine-
based ART between May 2005 and September 2007 and
had stored peripheral blood mononuclear cells (PBMCs)
and plasma collected at week 12 of ART were included in
this study. Women in the parent ART cohort gave consent
at enrollment for long-term storage of samples and for
additional studies including genetic testing. The present
study was approved as a protocol modification by the Uni-
versity of Washington Human Subjects Research Commit-
tee and Kenya Medical Research Institute’s Ethics and
Research Committee.
Determination of plasma nevirapine levels
Blood plasma collected 10–14 weeks after ART initiation
was used for the determination of plasma nevirapine
concentrations. Blood collection was not timed in rela-
tion to medication dosing, since this pharmacological
study was a secondary use of stored samples and data.
However, most women attended clinic in the morning,
and are likely to have been sampled between 2 and
4 hours after pill ingestion, at an optimal sampling time
for nevirapine [37]. Plasma nevirapine concentrations
were quantified using a reversed phase high performance
liquid chromatographic method adapted from the
method of Minzi and Ngaimisi [38]. Calibration curves
obtained for nevirapine-spiked plasma samples were lin-
ear, with correlation coefficients (r2) in the range of
0.993–0.996 and a limit of quantitation of 0.86 μg/mL.
The intra-day and inter-day precision (CV%) ranged
from 6.08–7.96 and 4.72–7.32, respectively. Intra-day
and inter-day accuracy (RD%) ranged from 3.47–5.51
and 2.00–8.10, respectively. The mean recovery for low,
medium and high concentrations of nevirapine was in
the range of 96–110%.
DNA preparation and genotyping procedures
DNA was extracted from PBMCs using the QIAamp
DNA blood mini-kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s protocol. The extracted
DNA was quantified using a UV spectrophotometer ND-
1000 (NanoDrop Technologies, Wilmington, DE, USA)at 260 nm and normalized to a concentration of 20 ng/
mL. Genotyping was carried out on an ABI 7500 Fast
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). SNPs were analyzed using the validated
Taqman Genotyping Assays purchased from Applied
Biosystems for CYP2B6 516G>T (rs3745274; assay ID
C_7817765_60) and CYP2B6 983T>C (rs28399499; assay
ID C_60732328_20), according to the manufacturer’s
instructions.
Definitions
CYP2B6 516G>T and 983T>C genotypes were described
as homozygous wild type for the G or T alleles (516GG
or 983TT), heterozygous (516GT or 983TC), or homo-
zygous mutated (516TT, 983CC). CYP2B6 metabolic
phenotypes were inferred from composite CYP2B6 ge-
notypes as previously described [22]. Those with no vari-
ant alleles at either positions (516GG or 983TT) were
classified as “extensive metabolizers.” The term “inter-
mediate metabolizers” described those with a single vari-
ant allele at either position, but not both. The term
“slow metabolizers” described those with two variant al-
leles (516TT, 983CC, or 516GT with 983TC).
Changes in CD4 cell count and PVL were assessed
at months 3, 6, and 12. Viral suppression was defined
as <100 copies HIV-1 RNA per mL of plasma. Hepatotox-
icity potentially attributable to ART was defined as a nor-
mal ALT at baseline with an elevation above the upper
limit of normal during treatment. A possible ART-related
skin rash was defined as no rash at baseline followed by
rash during treatment. Plasma or genital drug resistance
was defined as identification of drug resistance muta-
tions in plasma or genital secretions before or during
treatment.
Data analysis
The prevalence of each genetic variant was estimated
from the total number of copies of individual alleles di-
vided by the number of all alleles in the study popula-
tion. Deviation of genotypes from HW equilibrium
expectation was estimated using Stata’s hwsnp com-
mand, which calculates an exact HW significance prob-
ability. Prevalence estimates were reported with exact
binomial confidence intervals. Steady-state plasma nevi-
rapine levels were tested for normality by the Shapiro-
Wilk test, and subsequently log10-transformed due to
lack of normality. All averages are hence presented as
the geometric mean. Women with undetectable levels of
nevirapine were excluded from analysis, because it was
assumed that they were non-adherent to treatment.
One-way analysis of variance was used to determine
whether there were significant differences in continuous
variables across genotype or phenotypes groups. The ef-
fects of each genotype or phenotype on plasma nevirapine
Oluka et al. AIDS Research and Therapy  (2015) 12:10 Page 8 of 9levels at week 12 and on change in CD4 cell count at
month 3, 6 and 12 were evaluated using Stata’s qtlsnp
command, which assumes a co-dominant genetic model
and tests for an additive effect, a dominant effect and that
both effects are equal to zero (this last comparison is
equivalent to comparing means across the three possible
genotypes and phenotypes). We also modeled the relation-
ship between plasma nevirapine levels and post-ART out-
comes including change in CD4 count, plasma viral load,
and viral suppression using GEE models with a logit or
identify link, independent correlation matrix, and robust
standard error estimates. We adjusted these models for
month since ART initiation, time-updated adherence by
pill count, and either baseline CD4 count or plasma viral
load, as appropriate. To determine whether plasma nevira-
pine levels acted as a mediator in the association between
CYP2B6 983T>C genotype and change in CD4 cell count,
the effect of adding log10-transformed plasma nevirapine
levels to multivariable modeling was also evaluated by
GEE analysis.
The correlation between log10-transformed plasma ne-
virapine levels and age, BMI, change in CD4 cell count,
and change in log10-transformed PVL at months 3, 6
and 12 was evaluated with the Pearson’s test for correl-
ation. An independent t test was used to compare log10-
transformed nevirapine levels in women with suppressed
versus unsuppressed PVL. Logistic regression was used
to test for associations between log10-transformed
plasma nevirapine levels and the development of ALT
elevation, skin rash, or plasma or genital drug resistance
after treatment initiation. The modeled binary outcomes
were adjusted for potential confounding factors appro-
priate to the outcome being evaluated. In the analysis
of hepatotoxicity, the presence of hepatitis B infection
was included in the model as a potential effect modi-
fier. Data were analyzed using Stata version 11.2 (Stata
Corp, College Station, Texas, USA).
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